Search clinical trials for: Enteric-coated Mycophenolate Acid (EC-MPA)

Total 142 results

Novartis Pharmaceuticals

Terminated

A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms

Renal Transplantation

United States
Third Affiliated Hospital, Sun Yat-Sen University
Beijing Friendship Hospital; Beijing YouAn Hospital; RenJi Hospital; Huashan Hospital and other collaborators

Recruiting

Long-term Benefit of MPA in Liver Transplantation

Liver Transplant Rejection | Immunosuppressant Adverse Reaction

China
Novartis

Completed

Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil

Maintenance Kidney Transplant

Switzerland
Novartis Pharmaceuticals

Completed

Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation

Renal Transplant

United Kingdom
Novartis Pharmaceuticals

Completed

Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms

Renal Transplant

Korea, Republic of
Novartis Pharmaceuticals

Completed

Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)

Kidney Maintenance Transplant
Novartis

Completed

Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric-coated Mycophenolate Sodium With Standard Steroid Therapy in de Novo Kidney Recipients

Renal Transplantation
Novartis

Completed

Extension Study to Assess Tolerability and Safety of Enteric-coated Mycophenolate Sodium in Renal Transplant Recipients Who Received Mycophenolate Mofetil

Renal Transplantation
Novartis

Completed

Extension Study on the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients

Renal Transplantation
Novartis Pharmaceuticals

Completed

Enteric-coated Mycophenolate Sodium (EC-MPS) and Mycophenolate Mofetil (MMF) in Renal Transplant Patients With Gastrointestinal (GI) Intolerance

Renal Transplantation

United States
Novartis Pharmaceuticals

Completed

A Study to Investigate the Tolerability and Safety of Converting Stable Renal Transplant Recipients Who Receive Tacrolimus With or Without Corticosteroids From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS)

Renal Transplantation
Novartis

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

De Novo Kidney Transplant Recipients
Novartis

Completed

Extension Study of the Safety and Efficacy of Enteric-coated Mycophenolate Sodium in Kidney Transplant Recipients

Renal Transplantation
Novartis

Completed

Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)

Renal Transplantation | Gastrointestinal Problems

Germany, Switzerland
Novartis

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

Renal Transplantation

Switzerland
Novartis

Completed

Extension Study on the Efficacy and Safety of Enteric-coated Mycophenolate Sodium Administered in de Novo Kidney Transplant Patients

De Novo Kidney Transplantation
Novartis

Completed

Safety and Tolerability of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients With GI Intolerance

Renal Transplantation

United States
Zhishui Chen

Not yet recruiting

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant Recipients

Kidney Transplant Rejection
Novartis

Completed

Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) Therapy

Liver Transplantation | Kidney Transplantation

Switzerland
Novartis Pharmaceuticals

Completed

Measurement of Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Liver Transplant Recipients

Liver Transplantation

Germany
Novartis Pharmaceuticals

Completed

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants

Kidney Transplantation | Pancreas Transplantation

Germany
Novartis

Completed

A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.

Kidney Transplantation
Novartis Pharmaceuticals

Completed

An Open Label Study to Evaluate the Tolerability and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion (CsA-ME) in Maintenance Renal Transplant Recipients

Kidney Transplant Recipients
Novartis Pharmaceuticals

Completed

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant Patients

Kidney Transplantation

Switzerland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant Recipients

Kidney Transplant

Korea, Republic of
Novartis Pharmaceuticals

Terminated

MYPROMS-ES02: Safety and Efficacy of Basiliximab, Cyclosporine Microemulsion and Enteric-coated Mycophenolate Sodium (EC-MPS) Versus EC-MPS and Steroid Therapy in Kidney Transplant Recipients Who Are Hepatitis C Positive

De Novo Kidney Transplant
Novartis

Completed

Extension Study of Enteric-coated Mycophenolate Sodium in Combination With Full Dose or Reduced Dose Cyclosporine Microemulsion in Patients With de Novo Kidney Transplants

Renal Transplantation
Novartis

Completed

Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients

Kidney Transplantation

Switzerland
Novartis Pharmaceuticals

Completed

Study to Evaluate the Combination of Enteric-coated Mycophenolate Sodium (EC-MPS), Basiliximab, and C2-monitored Cyclosporine in de Novo Renal Transplant Recipients at Potential High Risk of Delayed Graft Function (DGF)

Renal Transplantation
Novartis Pharmaceuticals

Completed

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.

Kidney de Novo Transplant
Novartis Pharmaceuticals

Completed

Intensified vs. Standard Dose Therapy With Mycophenolate Sodium Plus Cyclosporin Microemulsion and Corticosteroid Combination in Patients With de Novo Renal Transplant Patients

Renal Transplantation

Germany
Guangzhou Yipinhong Pharmaceutical CO.,LTD

Unknown

The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B

Chronic Hepatitis B

China
University of Pennsylvania
Novartis Pharmaceuticals

Terminated

Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients

Transplants and Implants

United States
R. Mark Ghobrial, MD
Novartis

Completed

Myfortic, Prograf, and Corticosteroids in de Novo Liver Transplantation

End Stage Liver Disease

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in Comparison to Mycophenolate Mofetil (MMF) in de Nove Heart Patients

Heart Transplantation

United States, Australia, Argentina, Canada
Novartis Pharmaceuticals

Completed

Study of Enteric-coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Adult de Novo Renal Transplant Patients

Renal Transplant

China
Novartis Pharmaceuticals

Completed

Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A0107

Renal Transplant
Novartis

Completed

Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A302

Renal Transplant
Novartis

Completed

Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium After Equimolar Conversion From Mycophenolate Mofetil (MMF) in Patients With Renal Transplant

Prevention of Acute Rejection After Kidney Transplantation
Novartis Pharmaceuticals

Completed

Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate

Autoimmune Disease

Germany
Novartis

Completed

Clinical Study to Evaluate the Tolerability, Safety and Efficacy of Enteric-coated Mycophenolate Sodium, After Equimolar Conversion From Mycophenolate Mofetil (MMF), in Patients With Stable Renal Transplant Receiving Tacrolimus

Prevention of Acute Rejection After Kidney Transplantation
Novartis

Completed

Follow-up Study of Safety of Enteric-coated Mycophenolate Sodium in Patients Who Successfully Completed Study CERL080A301

Renal Transplant
Novartis

Completed

Safety and Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) Plus Valsartan in Patients With Kidney Transplants (MYTHOS

De Novo Renal Transplantation
East Carolina University
Novartis Pharmaceuticals

Completed

Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)

Transplant; Failure, Kidney

United States
Novartis

Completed

Study of Enteric-coated Mycophenolate Sodium Maintenance Therapy in Patients With Renal Transplant Receiving Cyclosporine Microemulsion and Steroids,

Maintenance Renal Transplantation
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.

Renal Transplantation

France
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant Recipients

Chronic Renal Failure

Israel
Novartis

Completed

Study of Enteric-Coated Mycophenolate Sodium (EC-MPS) Plus Reduced-dose Cyclosporine Microemulsion (CsA-ME) Compared to EC-MPS Plus Standard Dose CsA-ME in Eldery de Novo Renal Transplant Recipients Treated With Basiliximab and Short-term Steroids

Denovo Renal Transplantation
Novartis Pharmaceuticals

Terminated

Efficacy and Tolerability of Full Dose Enteric-coated Mycophenolate Sodium, in Addition to Cyclosporine for Microemulsion Reduced Dose, in Maintenance Renal Transplant Recipients

Kidney Transplantation

Italy
University Hospital, Tours

Not yet recruiting

Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies (INSTEAD)

Renal Transplant Rejection | Induction Therapy

3

Subscribe